UNITED STATES SECURITIES AND EXCHANGE COMMISSION April 20, 2018

ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934

Seattle Genetics, Inc. File No. 000-32405 - CF#35637

Seattle Genetics, Inc. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 10-Q filed on November 6, 2017, as amended April 13, 2018.

Based on representations by Seattle Genetics, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:

Exhibit 2.1	through November 6, 2022
Exhibit 10.1	through November 6, 2022
Exhibit 10.3	through November 6, 2022

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields Secretary